blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3456717

EP3456717 - 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE [Right-click to bookmark this link]
Former [2019/12]TABLETS CONTAINING 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CANCER
[2020/43]
StatusNo opposition filed within time limit
Status updated on  21.01.2022
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  12.02.2021
FormerGrant of patent is intended
Status updated on  01.10.2020
FormerExamination is in progress
Status updated on  06.12.2019
FormerRequest for examination was made
Status updated on  27.09.2019
FormerThe application has been published
Status updated on  15.02.2019
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
GILEAD SCIENCES, INC.
333 Lakeside Drive Foster City
California 94404 / US
[2019/12]
Inventor(s)01 / BACON, Elizabeth, M.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
02 / BALAN, Gayatri
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
03 / CHOU, Chien-Hung
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
04 / CLARK, Christopher, T.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
05 / COTTELL, Jeromy, J.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
06 / KIM, Musong
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
07 / KIRSCHBERG, Thorsten, A.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
08 / LINK, John, O.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
09 / PHILLIPS, Gary
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
10 / SCHROEDER, Scott, D.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
11 / SQUIRES, Neil, H.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
12 / STEVENS, Kirk, L.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
13 / TAYLOR, James, G.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
14 / WATKINS, William, J.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
15 / WRIGHT, Nathan, E.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
16 / ZIPFEL, Sheila, M.
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA California 94404 / US
 [2019/12]
Representative(s)Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2019/12]
Application number, filing date18186568.430.06.2016
[2019/12]
Priority number, dateUS201562189158P06.07.2015         Original published format: US 201562189158 P
US201562269060P17.12.2015         Original published format: US 201562269060 P
[2019/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3456717
Date:20.03.2019
Language:EN
[2019/12]
Type: B1 Patent specification 
No.:EP3456717
Date:17.03.2021
Language:EN
[2021/11]
Search report(s)(Supplementary) European search report - dispatched on:EP05.02.2019
ClassificationIPC:C07D401/14, C07D405/14, C07D413/14, C07D401/12, C07D409/14, C07D417/14, C07D471/04, C07D495/04, C07D498/04, A61K31/4709, A61P35/00, A61P29/00
[2020/43]
CPC:
C07D498/04 (EP,IL,US); C07D215/44 (BR); C07D401/14 (EP,CN,IL,KR,US);
A61K31/4709 (KR); A61P1/00 (EP,IL); A61P1/02 (EP,IL);
A61P1/04 (EP,IL); A61P1/06 (EP,IL); A61P1/08 (EP,IL);
A61P1/12 (EP,IL); A61P1/16 (EP,IL); A61P11/00 (EP,IL);
A61P11/06 (EP,IL); A61P13/12 (EP,IL); A61P17/00 (EP,IL);
A61P17/06 (EP,BR,IL); A61P17/14 (EP,IL); A61P19/02 (EP,IL);
A61P19/06 (EP,IL); A61P19/08 (EP,IL); A61P21/02 (EP,IL);
A61P21/04 (EP,IL); A61P25/00 (EP,IL); A61P25/04 (EP,IL);
A61P25/28 (EP,IL); A61P27/02 (EP,IL); A61P29/00 (EP,BR,CN,IL,KR);
A61P3/00 (EP,IL); A61P3/02 (EP,IL); A61P3/10 (EP,IL);
A61P31/04 (EP,BR,IL); A61P35/00 (EP,BR,CN,IL,KR); A61P37/00 (BR);
A61P37/02 (EP,IL); A61P43/00 (EP,BR,IL); A61P5/50 (EP,IL);
A61P7/00 (EP,IL); A61P7/06 (EP,IL); A61P9/00 (EP,IL);
A61P9/06 (EP,IL); C07B59/002 (IL,US); C07D215/42 (BR);
C07D401/12 (EP,IL,US); C07D405/14 (EP,CN,IL,KR,US); C07D409/14 (EP,CN,IL,KR,US);
C07D413/14 (EP,CN,IL,US); C07D417/14 (EP,CN,IL,US); C07D471/04 (EP,IL,US);
C07D495/04 (EP,CN,IL,US); C07B2200/05 (IL,US) (-)
Former IPC [2019/12]C07D401/14, C07D405/14, C07D413/14, C07D401/12, C07D409/14, C07D417/14, C07D471/04, C07D495/04, A61K31/4709, A61P29/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/44]
Former [2019/12]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Validation statesMA19.09.2019
TitleGerman:4,6-DIAMINO-CHINOLIN-3-CARBONITRIL DERIVAT ALS KREBS OSAKA THYROID (COT) MODULATOR ZUR BEHANDLUNG VON ENTZÜNDLICHER ERKRANKUNG[2021/10]
English:4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE[2021/10]
French:DÉRIVÉ DE 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE EN TANT QUE MODULATEUR DE CANCER OSAKA THYROID (COT) POUR LE TRAITEMENT DE MALADIE INFLAMMATOIRE[2021/10]
Former [2019/12]TABLETTEN ENTHALTEND 4,6-DIAMINO-CHINOLIN-3-CARBONITRIL DERIVATE ALS KREBS OSAKA THYROID (COT) MODULATOREN ZUR BEHANDLUNG VON KREBS
Former [2019/12]TABLETS CONTAINING 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CANCER
Former [2019/12]COMPRIMÉS CONTAINANT DÉRIVÉS DE 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE EN TANT QUE MODULATEURS DE CANCER OSAKA THYROID (COT) POUR LE TRAITEMENT DU CANCER
Examination procedure19.09.2019Amendment by applicant (claims and/or description)
19.09.2019Examination requested  [2019/44]
19.09.2019Date on which the examining division has become responsible
10.12.2019Despatch of a communication from the examining division (Time limit: M02)
28.01.2020Reply to a communication from the examining division
06.05.2020Despatch of a communication from the examining division (Time limit: M02)
29.06.2020Reply to a communication from the examining division
02.10.2020Communication of intention to grant the patent
27.01.2021Fee for grant paid
27.01.2021Fee for publishing/printing paid
27.01.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP16738976.6  / EP3191470
Divisional application(s)EP21162393.9  / EP3896064
Opposition(s)20.12.2021No opposition filed within time limit [2022/08]
Fees paidRenewal fee
31.07.2018Renewal fee patent year 03
27.06.2019Renewal fee patent year 04
29.06.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.06.2016
AL17.03.2021
CY17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
MK17.03.2021
MT17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
LU30.06.2021
IS17.07.2021
[2024/42]
Former [2024/23]HU30.06.2016
AL17.03.2021
CY17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
MK17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
LU30.06.2021
IS17.07.2021
Former [2023/33]HU30.06.2016
AL17.03.2021
CY17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
LU30.06.2021
IS17.07.2021
Former [2023/30]AL17.03.2021
CY17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
LU30.06.2021
IS17.07.2021
Former [2022/23]AL17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
LU30.06.2021
IS17.07.2021
Former [2022/18]AL17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
LU30.06.2021
Former [2022/10]AL17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
Former [2022/08]AL17.03.2021
DK17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
IS17.07.2021
Former [2022/07]AL17.03.2021
EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
MC17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
IS17.07.2021
Former [2021/51]EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
IS17.07.2021
Former [2021/50]EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
RO17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
Former [2021/48]EE17.03.2021
FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
Former [2021/46]FI17.03.2021
HR17.03.2021
LT17.03.2021
LV17.03.2021
RS17.03.2021
SM17.03.2021
BG17.06.2021
Former [2021/37]FI17.03.2021
HR17.03.2021
LV17.03.2021
RS17.03.2021
BG17.06.2021
Former [2021/36]FI17.03.2021
HR17.03.2021
BG17.06.2021
Former [2021/35]FI17.03.2021
HR17.03.2021
Former [2021/33]FI17.03.2021
Documents cited:Search[A]WO9843960  (AMERICAN CYANAMID CO [US]);
by applicantUS3845770
 US4326525
 US4902514
 US4992445
 US5001139
 US5023252
 US5616345
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.